Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

NCT04203316 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

1

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DRUG: Enasidenib
DRUG: Enasidenib Mesylate

Sponsor

Children's Oncology Group

Collaborators

[object Object]